- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 241/50 - Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to ring nitrogen atoms
Patent holdings for IPC class C07D 241/50
Total number of patents in this class: 20
10-year publication summary
|
0
|
3
|
2
|
1
|
2
|
1
|
1
|
1
|
0
|
0
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Takeda Pharmaceutical Company Limited | 2712 |
2 |
| Purdue Research Foundation | 3916 |
2 |
| Emory University | 1719 |
2 |
| Samsung Display Co., Ltd. | 38627 |
1 |
| The Regents of the University of California | 20745 |
1 |
| Janssen Pharmaceutica N.V. | 3168 |
1 |
| Merck Patent GmbH | 5728 |
1 |
| British Columbia Cancer Agency Branch | 182 |
1 |
| Eindhoven University of Technology | 14 |
1 |
| Forma Therapeutics, Inc. | 147 |
1 |
| Lycera Corporation | 31 |
1 |
| FUJIFILM Toyama Chemical Co., Ltd. | 114 |
1 |
| Abbisko Therapeutics Co., Ltd. | 119 |
1 |
| SpringWorks Therapeutics, Inc. | 156 |
1 |
| Nimbus Artemis, Inc. | 4 |
1 |
| Taros Chemicals GmbH & Co. KG | 4 |
1 |
| Merck Sharp & Dohme LLC | 3734 |
1 |
| Other owners | 0 |